Review of siltuximab in the treatment of multicentric Castleman’s disease

Sarosiek, Shayna; Shah, Ruchit N.; Munshi, Nikhil C.

doi:10.1177/2040620716653745

Cited by 41 publications

(41 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, it is the only monoclonal antibody drug with FDA approval for the treatment of CAR T-cell-induced CRS. [1][2][3][4][5][6]12,13 Based on the potential role of tocilizumab in the management of CRS, the main role of IL-6 in CRS, and the marked role of CRS in the pathophysiology of ARDS of SARS-CoV-2, we aimed to review the current evidence concerning the safety and efficacy of the use of tocilizumab in the management of ARDS in patients with COVID-19.…”

mentioning

confidence: 99%

A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome

Khiali

Khani

Entezari‐Maleki

2020

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Currently,the world is facing the pandemic of a novel strain of beta-coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute respiratory distress syndrome (ARDS) is the most devastating complication of SARS-CoV-2. It was indicated that cytokine-release syndrome and dominantly interleukin (IL)-6 play a central role in the pathophysiology of ARDS related to the novel 2019 coronavirus disease (COVID-19). Despite the global emergency of the disease, at this time, there are no proven therapies for the management of the disease. Tocilizumab is a potential recombinant monoclonal antibody against IL-6 and currently is under investigation for the management of ARDS in patients with COVID-19. Given these points, we reviewed the current evidence regarding the potential therapeutic role of tocilizumab and its important clinical issues in the treatment of ARDS related to COVID-19.

show abstract

mentioning

confidence: 99%

A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome

Khiali

Khani

Entezari‐Maleki

2020

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…However, pretreatment monitoring of haematological parameters in all patients before initiating siltuximab is recommended. 9,21 Increase of liver enzymes was recorded in two patients, leading to discontinuation in one patient.…”

Section: Discussionmentioning

confidence: 99%

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials

Rhee

Casper

Voorhees

et al. 2020

The Lancet Haematology

View full text Add to dashboard Cite

“…Another potential option for reducing inflammation is Siltuximab, a chimeric monoclonal antibody (mAb) that binds to and halts the effect of IL-6 (Sarosiek, Shah, & Munshi, 2016;.…”

Section: Drugs Targeting the Inflammatory Responses And Cytokine Stormmentioning

confidence: 99%

Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review

Sohag

Hannan

Rahman

et al. 2020

Drug Development Research

View full text Add to dashboard Cite

Coronavirus disease‐19 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is one of the most contagious diseases in human history that has already affected millions of lives worldwide. To date, no vaccines or effective therapeutics have been discovered yet that may successfully treat COVID‐19 patients or contain the transmission of the virus. Scientific communities across the globe responded rapidly and have been working relentlessly to develop drugs and vaccines, which may require considerable time. In this uncertainty, repurposing the existing antiviral drugs could be the best strategy to speed up the discovery of effective therapeutics against SARS‐CoV‐2. Moreover, drug repurposing may leave some vital information on druggable targets that could be capitalized in target‐based drug discovery. Information on possible drug targets and the progress on therapeutic and vaccine development also needs to be updated. In this review, we revisited the druggable targets that may hold promise in the development of the anti‐SARS‐CoV‐2 agent. Progresses on the development of potential therapeutics and vaccines that are under the preclinical studies and clinical trials have been highlighted. We anticipate that this review will provide valuable information that would help to accelerate the development of therapeutics and vaccines against SARS‐CoV‐2 infection.

show abstract

Review of siltuximab in the treatment of multicentric Castleman’s disease

Cited by 41 publications

References 28 publications

A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome

A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials

Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review

Contact Info

Product

Resources

About